Saturday 17 October 2026 Export ORKA’s income statement to Excel — free account

Oruka Therapeutics, Inc.

In the quarter to June 2026, EPS fell 19.6% and free cash flow fell 43.0%, each against the same quarter a year earlier.

71.93 1.94 −2.63%

Follow ORKA

Alert me

Market cap: $4.9B
P/E: 0.0×
Fwd P/E: —
Dividend yield: 0.00%
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 336.97

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	1	2	1	6	1	4	7	4	3	9	3

Insider Ownership 6.49%

Capital & Financial Ratios $m

Market Cap 4,890.00

Revenue —

Net Income (132.89)

Free Cash Flow (101.15)

Net Debt (873.56)

Current Ratio 38.51

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 4.07

Past 5Y EPS Growth —

This Y EPS Growth (29.94%)

Next Y EPS Growth (17.62%)

Next Y revenue growth —

Next 5Y EPS Growth (25.11%)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 94.14%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate 0.00

Annual Dividend Yield 0.00%

	total	individual payouts
2024	1.59	1.59
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	37	376	337	874
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	0	—	—	—
	38	377	344	885

	2023	2024	2025	Q'26
Payables	0	9	4	8
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	13	15	23

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	28.63%	58.94%	124.56%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(24)	(33)	—	—	—
’25	(21)	(23)	(22)	(23)	(88)
’24	(2)	(3)	(35)	(19)	(58)
’23	(2)	(1)	(2)	(1)	(5)
’22	(4)	(3)	(2)	(1)	(11)
’21	(5)	(4)	(5)	(5)	(19)
’20	(2)	(1)	(2)	(3)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(24)	(33)	—	—	—
’25	(21)	(23)	(22)	(23)	(88)
’24	(2)	(3)	(35)	(19)	(58)
’23	(2)	(1)	(2)	(1)	(5)
’22	(4)	(3)	(2)	(1)	(11)
’21	(5)	(4)	(5)	(5)	(19)
’20	(2)	(1)	(2)	(3)	(8)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.48)	(0.55)	—	—	—
’25	(0.40)	(0.46)	(0.55)	(0.54)	(1.85)
’24	(1.68)	(6.96)	(1.46)	(0.49)	(5.79)
’23	(1.08)	(1.20)	(1.20)	(0.96)	(4.44)
’22	(2.76)	(2.64)	(1.92)	(0.96)	(8.28)
’21	(3.96)	(4.08)	(3.96)	(4.80)	(16.69)
’20	(9.96)	(8.76)	(3.96)	(7.32)	(24.85)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	464.40	226.80	56.16	58.68	26.52	25.68	20.52	19.32	17.64	5.49	Analyst estimates 2026–2028 Powerpack
	High	1,062.72	626.40	421.20	245.40	264.00	66.00	31.08	32.40	53.88	32.64
People
People	Employees	20	20	15	13	14	19	12	5	36	68
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(16)	(19)	(8)	(6)	(10)	(19)	(10)	(5)	(84)	(105)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(16)	(18)	(8)	(5)	(10)	(19)	(10)	(5)	(84)	(105)
	Depreciation	0	0	0	0	0	0	0	0	(2)	(5)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(390.80)	(382.17)	(123.07)	(49.82)	(24.85)	(16.69)	(8.28)	(4.44)	(5.79)	(1.85)
	Cash flow	(356.83)	(361.74)	(128.61)	(43.65)	(19.69)	(16.20)	(9.09)	(4.18)	(3.44)	(1.93)
	Capex	(0.29)	(0.06)	(0.06)	(0.04)	(0.05)	(0.04)	0.00	0.00	(0.01)	0.00
	Free cash flow	(357.12)	(361.80)	(128.67)	(43.68)	(19.74)	(16.24)	(9.09)	(4.18)	(3.46)	(1.94)
	Book value	528.43	212.73	94.10	69.18	118.59	44.07	34.72	30.83	22.77	10.35
	Shares, m	0	0	0	0	0	1	1	1	17	46
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(15)	(17)	(8)	(5)	(8)	(19)	(11)	(5)	(58)	(88)
	Capex	0	0	0	0	0	0	0	—	0	0
	Free cash flow	(15)	(17)	(8)	(5)	(8)	(19)	(11)	(5)	(58)	(88)
Balance, $m
Balance, $m	Working capital	19	10	6	8	46	51	42	37	364	328
	Total debt	—	—	—	0	0	0	0	—	—	—
	Net debt	(21)	(12)	(7)	(8)	(49)	(53)	(42)	(37)	(376)	(337)
	Shareholders’ equity	22	10	6	8	47	51	42	37	382	472
Returns, %
Returns, %	ROA	(51.23)	(99.96)	(82.68)	(71.38)	(33.03)	(36.68)	(20.26)	(13.19)	(38.59)	(23.84)
	ROIC	(1,007.09)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	(837.93)	(56.55)
	ROE	(54.57)	(113.89)	(97.30)	(80.37)	(35.98)	(39.61)	(21.41)	(13.57)	(40.22)	(24.86)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MIRM Mirum Pharmaceuticals, Inc.	$5.4B	— (loss-making)	— (loss-making)	+37.92% (above 0%: growing)	n/m	−681.46% (below 0%: shrinking)	82.78%	(24.14%)	Compare
ERAS Erasca, Inc.	$5.2B	— (loss-making)	—	—	n/m	−4.67% (below 0%: shrinking)	0.00%	0.00%	Compare
COGT Cogent Biosciences, Inc.	$5.1B	— (loss-making)	— (loss-making)	−69.41% (below 0%: shrinking)	n/m	−42.01% (below 0%: shrinking)	0.00%	0.00%	Compare
PTCT PTC Therapeutics, Inc.	$5.1B	— (loss-making)	110×	+101.55% (above 0%: growing)	n/m	+295.69% (above 0%: growing)	94.47%	41.32%	Compare
CRSP CRISPR Therapeutics AG	$5.0B	— (loss-making)	— (loss-making)	+1,041.37% (above 0%: growing)	n/m	+26.19% (above 0%: growing)	100.00%	(1,151.84%)	Compare
TVTX Travere Therapeutics, Inc.	$5.0B	— (loss-making)	196×	+48.17% (above 0%: growing)	n/m	+604.22% (above 0%: growing)	98.72%	2.33%	Compare
SRRK Scholar Rock Holding Corporation	$5.0B	— (loss-making)	— (loss-making)	+605.03% (above 0%: growing)	n/m	+8.88% (above 0%: growing)	0.00%	0.00%	Compare
ORKA Oruka Therapeutics, Inc.	$4.9B	— (loss-making)	—	—	n/m	−43.00% (below 0%: shrinking)	0.00%	0.00%
DFTX Definium Therapeutics, Inc.	$4.6B	— (loss-making)	—	—	n/m	−78.31% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$5.0B	—	—	+74.86%	—	+2.11%	41.39%	0.00%

All 614 Biotechnology stocks →

Oruka Therapeutics, Inc. (ORKA) key facts

Oruka Therapeutics, Inc. (ORKA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ORKA traded at $71.93, a market capitalization of $4.9 billion.
Oruka Therapeutics, Inc. does not currently pay a dividend.
Return on equity was −24.9% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.